Fredag 2 Oktober | 01:43:55 Europe / Stockholm
Est. tid*
2027-06-17 08:00 Bokslutskommuniké 2027
2027-03-11 17:50 Kvartalsrapport 2027-Q3
2026-12-17 17:50 Kvartalsrapport 2027-Q2
2026-09-30 - Extra Bolagsstämma 2027
2026-09-17 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2026-09-16 - Årsstämma
2026-09-10 - Kvartalsrapport 2027-Q1
2026-06-17 - Bokslutskommuniké 2026
2026-03-18 - Kvartalsrapport 2026-Q3
2025-12-18 - Kvartalsrapport 2026-Q2
2025-09-17 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2025-09-16 - Årsstämma
2025-09-11 - Kvartalsrapport 2026-Q1
2025-07-14 - Extra Bolagsstämma 2026
2025-06-18 - Bokslutskommuniké 2025
2025-03-13 - Kvartalsrapport 2025-Q3
2024-12-12 - Kvartalsrapport 2025-Q2
2024-09-18 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2024-09-17 - Årsstämma
2024-09-12 - Kvartalsrapport 2025-Q1
2024-07-15 - Extra Bolagsstämma 2025
2024-06-18 - Bokslutskommuniké 2024
2024-03-14 - Kvartalsrapport 2024-Q3
2023-11-28 - Kvartalsrapport 2024-Q2
2023-09-06 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2023-09-06 - Kvartalsrapport 2024-Q1
2023-09-05 - Årsstämma
2023-06-21 - Bokslutskommuniké 2023
2023-05-17 - Extra Bolagsstämma 2024
2023-03-16 - Kvartalsrapport 2023-Q3
2022-12-15 - Kvartalsrapport 2023-Q2
2022-11-07 - Extra Bolagsstämma 2022
2022-09-01 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2022-08-31 - Årsstämma
2022-08-31 - Kvartalsrapport 2023-Q1
2022-06-16 - Bokslutskommuniké 2022
2022-03-15 - Kvartalsrapport 2022-Q3
2021-12-01 - Kvartalsrapport 2022-Q2
2021-09-01 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2021-08-31 - Årsstämma
2021-08-31 - Kvartalsrapport 2022-Q1
2021-06-17 - Bokslutskommuniké 2021
2021-03-18 - Kvartalsrapport 2021-Q3
2020-12-03 - Kvartalsrapport 2021-Q2
2020-08-28 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2020-08-27 - Årsstämma
2020-08-27 - Kvartalsrapport 2021-Q1
2020-06-12 - Bokslutskommuniké 2020
2020-03-12 - Kvartalsrapport 2020-Q3
2019-12-05 - Kvartalsrapport 2020-Q2
2019-08-30 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2019-08-29 - Årsstämma
2019-08-29 - Kvartalsrapport 2020-Q1
2019-06-14 - Bokslutskommuniké 2019
2019-05-02 - Extra Bolagsstämma 2020
2019-03-21 - Kvartalsrapport 2019-Q3
2018-12-13 - Kvartalsrapport 2019-Q2
2018-08-31 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2018-08-30 - Årsstämma
2018-08-30 - Kvartalsrapport 2019-Q1
2018-06-15 - Bokslutskommuniké 2018
2018-03-21 - Kvartalsrapport 2018-Q3
2017-12-19 - Kvartalsrapport 2018-Q2
2017-09-01 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2017-08-31 - Årsstämma
2017-08-31 - Kvartalsrapport 2018-Q1
2017-06-14 - Bokslutskommuniké 2017
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Biovica International är ett läkemedelsbolag som inriktar sin forskning mot cancerbehandling. Bolaget utvecklar blodbaserade biomarkörtester för att övervaka och utvärdera cancerbehandlingar. Proven analyserar risken för utvecklingen av enzymet tymidinkinas, en enzym som har koppling till tumörers tillväxt. Huvudfokus återfinns inom behandling av bröstcancer. Biovica International grundades 2008 och har sitt huvudkontor i Uppsala.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Announcement from the extra general meeting in Biovica International AB

2026-09-30 15:00:00

The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 30 September 2026 and the following resolutions were passed by the meeting.

Approval of the board of directors' resolution on a rights issue of shares
The extra general meeting resolved to approve the board of directors' resolution on 9 September 2026 on a rights issue of a maximum of 97,303,733 shares. The subscription price to be paid for each share shall be SEK 0.30, in total SEK 29,191,119.90 if all shares are subscribed for. Through the new share issue, the Company's share capital may be increased by a maximum of SEK 6,486,915.537812.

Those who on the record date 5 October 2026 are recorded as a holder of shares in the share register kept by Euroclear Sweden AB shall have a preferential right to subscribe for new B shares at a subscription price of SEK 0.30 per share. Shareholders receive one (1) subscription right for each share, regardless of share class, held as of the record date. Three (3) subscription rights entitle the holder to subscribe for one (1) new B share in the rights issue.

Subscription for shares with subscription rights shall be made by payment in cash during the period from 7 October 2026 up until and including 21 October 2026. Subscription for shares without subscription rights shall be made on a special subscription list during the period from 7 October 2026 up until and including 21 October 2026.

Approval of the board of directors' resolution on a directed issue of shares
The extra general meeting resolved to approve the board of directors' resolution on 9 September 2026 on a directed issue of a maximum of 7,071,112 B shares with deviation from the shareholders' preferential rights. The total increase of the Company's share capital can amount to a maximum of SEK 471,407.466993. The subscription price for the new shares shall be SEK 0.30 per share, in total SEK 2,121,333.60 if all shares are subscribed for. Right to subscribe for the new shares, with deviation from the shareholders' preferential rights, shall be attributed to HDF Cancer Monitoring BV which is the Company's guarantor in the rights issue.

For detailed terms regarding the resolutions at the extra general meeting as described above, please refer to the notice and the complete proposals which are available on the Company's website, www.biovica.com.